...
首页> 外文期刊>BMC Infectious Diseases >Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study
【24h】

Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study

机译:住院患者耐甲氧西林金黄色葡萄球菌(MRSA)和广谱β-内酰胺酶(ESBL)肠杆菌科的院内获取:一项前瞻性多中心研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The risk of acquisition of antibiotic resistant-bacteria during or shortly after antibiotic therapy is still unclear and it is often confounded by scarce data on antibiotic usage. Primary objective of the study is to compare rates of acquisition of methicillin-resistant Staphylococcus aureus and extended spectrum beta-lactamase-producing Enterobacteriaceae in hospitalised patients, after starting antibiotic therapy. Methods/Design The study, running in three European hospitals, is a multicenter, prospective, longitudinal, observational cohort study funded from the European Community's Seventh Framework Programme [FP7/2007-2013] within the project 'Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria' (acronym SATURN). Nasal and rectal screening for methicillin-resistant Staphylococcus aureus and extended spectrum beta-lactamase-producing Enterobacteriaceae will be obtained at hospital admission, discharge, at antibiotic start (t0, within one hour) and at the following intervals: day 3 (t1), 7 (t2), 15 (t3), and 30 (t4). Two nested case-control studies will be performed. The objective of the first study will be to define individual level of risk related to specific antibiotics. Patients acquiring methicillin-resistant Staphylococcus aureus and extended spectrum beta-lactamase-producing Enterobacteriaceae (cases) will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (controls; ratio 1:4). To define the impact of antibiotics on new acquisition of target antibiotic-resistant bacteria, a second nested case-control study will be done (ratio 1:4). Control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at admission. Epidemiological, clinical and microbiological data will be prospective collected. Discussion The rationale of this study is to better understand the impact of antibiotic use on acquisition, selection and transmission of antimicrobial resistant-bacteria in European hospitals. Trial registration ClinicalTrials.gov NCT01208519 .
机译:背景技术目前尚不清楚在抗生素治疗期间或之后不久获得抗生素抗药性细菌的风险,并且常常因缺乏抗生素使用数据而感到困惑。该研究的主要目的是比较开始抗生素治疗后住院患者的耐甲氧西林金黄色葡萄球菌和产生广谱β-内酰胺酶的肠杆菌科细菌的获得率。方法/设计该研究在三所欧洲医院中进行,是一项多中心,前瞻性,纵向,观察性队列研究,由欧洲共同体第七框架计划[FP7 / 2007-2013]资助,项目为“特定抗生素治疗对患病率的影响”人宿主ResistaNt细菌(简称SATURN)的名称。入院,出院,开始抗生素治疗(t 0 ,一小时内)及以下时间进行耐甲氧西林金黄色葡萄球菌和产广谱β-内酰胺酶的肠杆菌科细菌的鼻和直肠筛查。时间间隔:第3天(t 1 ),7(t 2 ),15(t 3 )和30(t 4 )。将进行两个嵌套的病例对照研究。第一项研究的目的是确定与特定抗生素有关的个体风险水平。在开始抗生素治疗后,将获得耐甲氧西林金黄色葡萄球菌和产生超广谱β-内酰胺酶的肠杆菌科患者(病例)与未获得抗药性菌株的患者进行比较(对照;比例为1:4)。为了确定抗生素对新获得的靶标抗药性细菌的影响,将进行第二次嵌套病例对照研究(比率1:4)。对照组将在未接受抗生素的患者中选择,在相应病例的当天在同一病房接受治疗,入院时培养阴性。将会收集流行病学,临床和微生物学数据。讨论本研究的目的是为了更好地了解抗生素在欧洲医院中对抗菌素耐药菌的获取,选择和传播的影响。试用注册ClinicalTrials.gov NCT01208519。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号